Regulation

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Last chance on LABAs</h1><h2 class="title-bottom webtitle">FDA ordered safety studies for asthma drugs could be hugely expensive</h2><div class="byline">Aaron Bouchie Senior Writer</div><div class="date"></div></div></div></div>

cancer

Cardiovascular

Infectious

Inflammation

Ophthalmic

Pulmonary

Last chance on LABAs

FDA has concluded that now is the time for pharma companies to resolve the safety of the asthma drugs in post-marketing studies. Although the cost will be decided by the design, it's clear the studies won't be cheap and will divert resources from other drug development programs.

FDA ordered safety studies for asthma drugs could be hugely expensive

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>